



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/829,113	04/09/2001	William Edward Evans	44158/209598 (5853-3)	2302

826 7590 08/16/2002

ALSTON & BIRD LLP  
BANK OF AMERICA PLAZA  
101 SOUTH TRYON STREET, SUITE 4000  
CHARLOTTE, NC 28280-4000

EXAMINER

FREDMAN, JEFFREY NORMAN

ART UNIT

PAPER NUMBER

1637

DATE MAILED: 08/16/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/829,113

Applicant(s)

EVANS ET AL.

Examiner

Jeffrey Fredman

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 16 July 2002.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-18 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

**DETAILED ACTION**

***Election/Restrictions***

1. Applicant's election without traverse of Group I, claims 1-18 in Paper No. 8 is acknowledged.

***Claim Rejections - 35 USC § 103***

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 1-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Patel et al (Nucleic Acids Research (1991) 19:3561-3567) in view of Michalatos-Beloin et al (Nucleic Acids Res. (1996) 24:4841-4843).

Patel teaches a method of determining the haplotype structure of a contiguous DNA segment comprising a first nucleotide polymorphism and a second nucleotide

polymorphism separated by at least 200 nucleotides (see abstract and 3563, figure 2 which shows 1.1 kb fragment with polymorphisms at each end) comprising:

- (a) obtaining a DNA sample from a human source comprising said contiguous DNA segment (page 3562, subheading "DNA extraction"),
- (b) using said DNA sample as a template to form a product which is capable of being subject to intramolecular ligation (page 3562, subheading "Inverse PCR"),
- (c) ligating the ends of the DNA fragment to each other so as to produce a circular DNA molecule (page 3562, subheading "Inverse PCR"),
- (d) determining the haplotype of the first and second nucleotide polymorphism by allele specific PCR amplification (page 3562, subheading "Inverse PCR").

Patel further teaches that the method can be applied to sequences up to 10 kb apart and suggests that even larger regions can be used (page 3567, column 1, lines 6-9).

Patel teaches mutations which are substitutions of single nucleotides and where there are a series of nucleotide polymorphisms located between the two amplified polymorphisms (see page 3561, column 2 and page 3562, figure 1).

Patel teaches determining the presence of multiple different polymorphisms (see page 3565, column 1, subheading "Double ARMS Inverse PCR (DARMSI-PCR)").

Patel teaches amplification and detection of each haplotype in the same gene, the globin cluster (page 3562, figure 1).

Patel further teaches that the method can be used for diagnostic purposes (see page 3567, column 1).

Patel does not teach preparation of the template for intramolecular ligation by long range PCR.

Michalatos-Beloin teaches haplotyping methods where the molecules are prepared by long range PCR (page 4866, figures 2 and 3). Michalatos-Beloin also teaches that amplification of up to 40 kb should be possible (see page 4867, column 2).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to utilize the long range PCR method of Michalatos-Beloin to prepare the sample for the haplotyping method of Patel since Michalatos-Beloin states "The allele-specific long range PCR products were used as templates for amplification of the STR (page 4867, column 1)". An ordinary practitioner would have been motivated to use long range PCR as the template for the DARMSI-PCR method of Patel rather than genomic DNA in order to permit improved discrimination and detection as taught by Michalatos-Beloin (see page 4867, column 2) and since Michalatos-Beloin notes "The ability to isolate hemizygous DNA segments readily from heterozygous genomes via molecular haplotyping will provide the accuracy necessary in these diverse applications (page 4867, column 2). Thus, application of the method of Michalatos-Beloin to the inverse PCR method of Patel can be used to increase the accuracy of the Patel method.

5. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Patel et al (Nucleic Acids Research (1991) 19:3561-3567) in view of Michalatos-Beloin et al (Nucleic Acids Res. (1996) 24:4841-4843) as applied to claims 1-16 and further in view of Krynetski et al (Proc. Natl. Acad. Sci. (1995) 92:949-953).

Patel in view of Michalatos-Beloin teach the limitations of claims 1-16 as discussed above. Patel in view of Michalatos-Beloin do not teach application of the method to the TPMT gene.

Krynetski teaches that there are two haplotypes in the TPMT gene, one of which is associated with cytotoxicity in chemotherapeutic treatment using methylmercaptopurine (see page 949, columns 1 and 2).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to utilize the method of Patel in view of Michalatos-Beloin to haplotype the TPMT gene since Krynetski teaches "Identification of the inactivating mutations at the TPMT locus would not only provide important insights into the molecular mechanisms of this genetic polymorphism but might also offer a method of prospectively identifying heterozygotes and TPMT-deficient patients prior to treatment with potentially toxic dosages of mercaptopurine (page 949, column 2)". Thus, an ordinary practitioner would have been motivated to haplotype the TPMT gene using the method of Patel in view of Michalatos-Beloin, where Patel teaches that the method is useful "for routine diagnostic purposes (page 3567, column 1)", in order to diagnose patients who are TPMT deficient prior to toxic treatment.

6. Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Patel et al (Nucleic Acids Research (1991) 19:3561-3567) in view of Michalatos-Beloin et al (Nucleic Acids Res. (1996) 24:4841-4843) as applied to claims 1-16 and further in view of Martin et al (Am. J. Hum. Genet. (2000) 67:383-394).

Patel in view of Michalatos-Beloin teach the limitations of claims 1-16 as discussed above. Patel in view of Michalatos-Beloin do not teach application of the method to the listed genes.

Martin teaches haplotype analysis of the ApoE gene in order to analyze the presence of Alzheimer's disease (abstract).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to utilize the method of Patel in view of Michalatos-Beloin to haplotype the ApoE gene since Martini teaches "Haplotype analysis using family data increased significance over that seen in single-locus tests for some of the markers, and for these data, improved localization of the gene (abstract)." Thus, an ordinary practitioner would have been motivated to haplotype the ApoE gene using the method of Patel in view of Michalatos-Beloin, where Patel teaches that the method is useful "for routine diagnostic purposes (page 3567, column 1)", in order to diagnose patients who are at risk for Alzheimer's disease.

### ***Conclusion***


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is 703-308-6568. The examiner can normally be reached on 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Application/Control Number: 09/829,113  
Art Unit: 1637

Page 7

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.



Jeffrey Fredman  
Primary Examiner  
Art Unit 1637

August 9, 2002